Navigation Links
Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression
Date:7/27/2009

six-week period. Patients were randomized into one of three arms, BCI-952 (n=67), buspirone (n=34) or placebo (n=33). Co-primary endpoints were the Clinical Global Impression-Improvement (CGI-I) and the Quick Inventory of Depressive Symptomatology (QIDS SR-16). Secondary endpoints included the CGI-S, IDSC30 and HAMA. The data presented at the NCDEU meeting focused on the MITT population using both the LOCF and MMRM analyses for the co-primary endpoints.

The CGI-I at week six demonstrated improvement relative to placebo using the MITT LOCF, MITT MMRM. The mean CGI-I scores were statistically significant relative to placebo using the MITT MMRM (p=0.046).The responders analysis for CGI-I (SCORE <=2) demonstrated a higher response rate (58%) for BCI-952 as compared to buspirone alone (38%) (p=0.063) and placebo (36%) (p=0.055).

The QIDS SR16 demonstrated numerical improvement as compared to placebo; however these improvements were not statistically significant.

BCI-952 also demonstrated improvements on the secondary endpoints of the IDSC30, HAMA and CGI-S. These improvements were statistically significant for IDSC30 (p=0.034) and HAMA (p=0.041).

Results of this study in patients with MDD showed that BCI-952 demonstrated improvements in multiple endpoints of depression. In addition, BCI-952 was well tolerated with a safety profile similar to placebo.

About BrainCells Inc.

BrainCells Inc. (BCI) is a drug discovery and development company leading the scientific research of neurogenesis by applying its robust and proprietary platform technology to identify novel pathways for small molecule therapeutics to treat various central nervous system (CNS) diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictive screening platform, BCI can direct the selection and develop
'/>"/>

SOURCE BrainCells Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
2. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
3. CareFirst BCBS Covers eNO Measurement for Diagnosis, Asthma Treatment
4. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
5. Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations
6. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. First Potential Lupus-Specific Treatment in Sight
8. New Research Shows: Neurofeedback is an Evidence-Based Treatment for ADHD
9. Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV
10. Ipsogen Reports Incorporation of the Genomic Grade in the 2009 St. Gallen International Consensus Meeting on the Primary Treatment of Early Breast Cancer
11. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... HOUSTON , July 11, 2014  Kindred ... proud to announce the opening of its new ... provides outpatient services to people with chronic, hard ... wounds which can lead to amputation, lower leg ... which have delayed closure, and traumatic injury wounds ...
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... Four studies highlighting late-breaking research advances in the treatment ... at the 50th Annual Meeting of the American Society of ... Results from a study examining the ability of ... the inner lining of blood vessels, in patients with sickle ...
... at ASH Annual Meeting- , , ... announced results of a randomized phase III study presented ... of Hematology. The study in adult patients with hematological ... syndrome (TLS) demonstrated that Elitek(R) (rasburicase) significantly reduced plasma ...
Cached Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 2Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 3Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 4Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome 5
(Date:7/14/2014)... City, NJ (PRWEB) July 14, 2014 ... the established global leader in enterprise-class cloud management, ... collaboration platforms, today announced AvePoint software will be ... leading managed cloud specialist. , The ... Rackspace to offer the following AvePoint solutions to ...
(Date:7/14/2014)... 2014 Many diet plans often recommend eating ... the School of Public Health at the University of Alabama ... near-zero effect on weight loss. Now experts are suggesting that ... form of portion control to trigger measurable weight ... and controlling how much is consumed, simply by using a ...
(Date:7/14/2014)... Kenn Renner recently released a new video describing his ... the business on Austin Real Estate Investments . , ... Renner – is internationally recognized for his combined expertise on ... Investing in real estate is a great way for people ... career, while others like to do it as a hobby. ...
(Date:7/14/2014)... Seattle, WA (PRWEB) July 14, 2014 ... eat,' but what exactly does that mean?” This question ... and recently featured on Western Washington Medical Group’s blog ... with their mental health in mind . , According ... caffeinated beverages are placing themselves at a high risk ...
(Date:7/14/2014)... Milpitas, CA, and Washington DC (July 14, 2014) ... will be at Microsoft Worldwide Partner Conference 2014 (WPC) ... to showcase its award-winning information archiving and eDiscovery platforms ... 365, Windows servers, SharePoint, and Azure cloud network in ... “In the information archiving and legal discovery space for ...
Breaking Medicine News(10 mins):Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Drink With Your Mental Health in Mind, Advises an Article by Mental Health America Featured by Western Washington Medical Group 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5
... academics have been awarded funds from a huge European ... of individual people which could lead to everyone ... genetic and physiological make-up. Under the system, doctors ... of an individual patient,s health needs and medical history ...
... Steven Reinberg HealthDay Reporter , SUNDAY, July 24 ... new anti-clotting drug, Eliquis, to dual antiplatelet therapy may result ... and stroke, a new study finds. A trial evaluating ... severe bleeding among those taking Eliquis (apixaban) became apparent. ...
... July 23 (HealthDay News) -- Swimming may be easy on ... The most common injury among those who practice the ... percent of competitive swimmers, said Dr. Scott A. Rodeo, co-chief ... Special Surgery in New York City, who recently spoke at ...
... News) -- The ability of dolphins to resist infection and ... the treatment of human wounds, a researcher suggests. , ... documented," Dr. Michael Zasloff, adjunct professor at Georgetown University Medical ... news release. "How does the dolphin not bleed ...
... study by researchers at Drexel University,s School of Public Health ... gateway to the use of injected drugs such as heroin, ... drugs. The study, published in the International Journal of ... initiation into the misuse of opioid drugs. Common factors identified ...
... Amanda Gardner HealthDay Reporter , THURSDAY, July 21 ... Internet on their smartphones tend to hold the devices closer ... to work harder than usual, new research shows. This ... smartphones -- could put added strain on people who already ...
Cached Medicine News:Health News:Computer program could 'revolutionize the world's health care' 2Health News:Computer program could 'revolutionize the world's health care' 3Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 2Health News:Anti-Clotting Drug May Cause Severe Bleeding With No Benefit 3Health News:Common Swimming Injuries Often Avoidable 2Health News:Dolphins' Superior Ability to Heal May Help Humans 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 2Health News:Drexel study: Misuse of pain medication is pathway to high-risk behaviors 3Health News:Smartphones May Be Taxing Your Eyes 2Health News:Smartphones May Be Taxing Your Eyes 3
... valve is enclosed in a ... the valve from being accidentally ... or reclining positions. The valve ... free ensuring uninterrupted flow and ...
Intermittent catheter - Ready-to-Use Sterile, Enclosed System...
... The VerifyNow (Ultegra) System is ... which measures platelet induced aggregation as ... system consists of an instrument, a ... assay device contains reagents based on ...
... The Model 700 Whole Blood/Optical Lumi-Aggregometer available ... This new Aggregometer measures platelet function on ... blood or optical density in plasma with ... method. The Model 700 Aggregometer also has ...
Medicine Products: